TABLE 4.
Malignant cases
| Case | Age (years) | Sex | Location | Final diagnosis | LBC diagnosis | Therapy | Stage | Follow‐up periods (months) | Status | Recurrence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 53 | M | Pt | Invasive ITPN | Malignant (ca.) | Surgery + AC | IIA | 50.0 | Alive | Liver metastasis |
| 2 | 76 | F | Ph | Noninvasive IPMC | Malignant (adenoca.) | Surgery | 0 | 51.8 | Alive | No |
| 3 | 72 | M | Pt | PDAC | Indeterminate | NACRT + Surgery + AC | pCR | 13.2 | Alive | No |
| 4 | 75 | F | Pb | PDAC | Malignant (adenoca.) | Surgery + AC | IIA | 13.5 | Alive | No |
| 5 | 66 | M | Pb | PDAC | Malignant (adenoca.) | Surgery + AC | 0 (CIS) | 52.6 | Alive | No |
| 6 | 67 | F | Ph | PDAC | Malignant (adenoca.) | Surgery + AC | 0 (CIS) | 19.1 | Alive | No |
| 7 | 72 | F | Ph | PDAC | Malignant (adenoca.) | NACRT + Surgery + AC | IA | 40.6 | Alive | Peritoneal dissemination |
| 8 | 73 | M | Ph | PDAC | Indeterminate | Surgery + AC | IIB | 49.9 | Alive | No |
| 9 | 76 | F | Ph | PDAC | Malignant (adenoca.) | Surgery + AC | IIB | 34.1 | Alive | Lung metastasis |
| 10 | 76 | M | Pt | PDAC | Malignant (adenoca.) | NACRT + Surgery + AC | IA | 22.5 | Death | Lung metastasis, liver metastasis |
| 11 | 76 | M | Pt | PDAC | Malignant (adenoca.) | NACRT + Surgery + AC | IIB | 24.0 | Alive | No |
Abbreviations: AC, adjuvant chemotherapy; adenoca., adenocarcinoma; ca., carcinoma; IPMC, intraductal papillary mucinous carcinoma; IPMN, intraductal papillary mucinous neoplasm; ITPN, intraductal tubulopapillary neoplasm; LBC, liquid‐based cytology; NACRT, neoadjuvant chemoradiation therapy; Pb, pancreatic body; pCR, pathologically complete response after NACRT; PDAC, pancreatic ductal adenocarcinoma; Ph, pancreatic head; Pt, pancreatic tail.